Claims
- 1. 5-[1H-(5-membered-N-aromatic heteryl)-1-yl]-7-R'-1,6-naphthyridin-2(1H)-one having the formula I ##STR8## or pharmaceutically acceptable acid-addition or pharmaceutically acceptable cationic salt thereof, where R is hydrogen, halo or lower-alkyl, R' is hydrogen or methyl, R.sub.1 is hydrogen, lower-alkyl, hydroxymethyl, halo, trifluoromethyl, nitro or phenyl, Z is N, C-H, C-(lower-alkyl), C-halo, C-hydroxymethyl or C-phenyl, and Y is N, C-H, C-halo, C-(lower-alkyl) or C-NO.sub.2, at least one of Y or Z being N.
- 2. A compound according to claim 1 where Y is CH when Z is N, and R.sub.1 and R are each hydrogen or methyl.
- 3. 5-(1H-Imidazol-1-yl)-1,6-naphthyridin-2(1H)-one according to claim 1.
- 4. 5-(4-Methyl-1H-imidazol-1-yl)-1,6-naphthyridin-2(1H)-one according to claim 1.
- 5. 5-(2-Methyl-5-nitro-1H-imidazol-1-yl)-1,6-naphthyridin-2(1H)-one according to claim 1.
- 6. 5-(2-Methyl-1N-imidazol-1-yl)-1,6-naphthyridin-2(1H)-one according to claim 1.
- 7. 5-(1H-Pyrazol-1-yl)-1,6-naphthyridin-2(1H)-one according to claim 1.
- 8. 5-(1H-1,2,4-Triazol-1-yl)-1,6-naphthyridin-2(1H)-one according to claim 1.
- 9. 5-(4,5-Dimethyl-1H-imidazol-1-yl)-1,6-naphthyridin-2(1H)-one according to claim 1.
- 10. 5-(4-Phenyl-1H-imidazol-1-yl)-1,6-naphthyridin-2(1H)-one according to claim 1.
- 11. A cardiotonic composition for increasing cardiac contractility which comprises a pharmaceutically acceptable carrier and, as the active component thereof, a cardiotonically effective amount of 5-[1H-(5-membered-N-heteryl)-1-yl]-7-R'-1,6-naphthydridin-2(1H)-one of claim 1 or pharmaceutically acceptable acid-addition or cationic salt thereof.
- 12. A composition according to claim 11 where the active component is 5-(4-methyl-1H-imidazol-1-yl)-1,6-naphthyridin-2(1H)-one.
- 13. A method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient a cardiotonically effective amount of 5-[1H-(5-membered-N-heteryl)-1-yl]-7-R'-1,6-naphthyridin-2(1H)-one of claim 1 or pharmaceutically acceptable acid-addition or cationic salt thereof.
- 14. A method according to claim 13 where 5-(4-methyl-1N-imidazol-1-yl)-1,6-naphthyridin-2(1H)-one is administered.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a division of copending application Ser. No. 816,591, filed Jan. 6, 1986, now U.S. Pat. No. 4,634,772; in turn, a continuation-in-part of copending application Ser. No. 811,040, filed Dec. 19, 1985, now abandoned; in turn, a continuation-in-part of copending application Ser. No. 765,900, filed Aug. 14, 1985, now abandoned; in turn, a continuation-in-part of copending application Ser. No. 695,603, filed Jan. 28, 1985 and now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3993656 |
Rooney et al. |
Nov 1976 |
|
4415580 |
Lesher |
Nov 1983 |
|
Non-Patent Literature Citations (2)
Entry |
Czuba et al., Pol. J. Chem. 52, 2369-76 (1978). |
Paudler et al., J. Heterocyclic Chem. 2 (4), 393-8 (1965). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
816591 |
Jan 1986 |
|
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
811040 |
Dec 1985 |
|
Parent |
765900 |
Aug 1985 |
|
Parent |
695603 |
Jan 1985 |
|